Top GME Redditor DeepFuckingValue Names HGEN As A Top Pick - GME, AMC, EXPR, KOSS, LIVE

DeepFuckingValue, also known as Roaring Kitty, is the prolific GME investor who has led the shorting squeeze charge. A Reddit poster recently broke down his top picks outside of GME, as shown in an image of his notebook:




The one that stands out the most is HGEN. At the time of this note, HGEN was $19.59, trading slightly above where it is today. But the key difference being between now and last month is that HGEN announced Positive Phase 3 Topline Results Demonstrating That Lenzilumab™ Improves Survival Without Need for Mechanical Ventilation in Hospitalized Patients With COVID-19. The stock shot up to $29 on a short squeeze fueled rally after the news but pulled back as the company got 5 million shares of financing at $18.50 to raise $92.5 million. 

Usually investors view financing as bad news, but this is done with a distinct purpose. The company is going to be manufacturing Lenzilumab in advance of expected Emergency Use Authorization granted by the FDA. The timing of this grant is expected to happen in weeks, so speculative investors will be buying up the stock in anticipation of this decision.

In addition to being one of DFV's top picks, HGEN remains a strong short squeeze candidate. Shorts that were squeezed the first time around have been replenished by other shorts as shown on the daily volume report on nakedshortreport.com:










This is a chart of the share float and short interest of the top meme stocks and short squeeze candidates as of Wednesday's close:










GME remains the one with the highest short % of the float at 45%. HGEN is #2 with 26%. This is much greater than the numbers imply, showing that Yahoo believes that the float is much tighter or short interest is higher than actually reported. While AMC has a lot of short interest, its short % is down to 11%. This is indicative of the heavy dilution that took place. People who are betting on AMC to run on a short squeeze are just wasting their time. Shorts will cover into the heavy dilution at low prices, not on the open market at high prices on a squeeze. 

LIVE remains a dark horse play. The short interest is low, but it doesn't really need short interest because of its extremely small float of only 1.27 million shares. KOSS has generally had a low short interest but that didn't stop the stock from running to over $100 from $10. LIVE's float is less than half of KOSS. Also LIVE is the only one in the group that has earnings and a P/E ratio. Most P/E ratios are around 20 so LIVE being at only 5 makes the stock four times undervalued. We think it can reach $100 to come more in line with average P/E ratio numbers. 

Comments

Post a Comment

Popular posts from this blog

Carvana: The Gamma Squeeze is Real, Time to Bankrupt Kerrisdale

Image
Heavily shorted Carvana Co. (CVNA) is in the middle of a squeeze. One that looks eerily similar to the beginnings of the one we saw on GME that eventually made it run to $400 and took down Melvin Capital. Once again certain market players or commentators who focus on fundamentals and who misunderstand or downplay the short squeeze thesis will only add fuel to the fire as they short the stock. Will Carvana be able to refinance its debts next year? Will it become profitable by then? Who knows, and who cares. 2024 isn't the timeline here. The timeline starts as early as June 16, 2023. Triple witching day on options. This time Kerrisdale Capital is the target. The firm is in a desperate spot because the last short call it made was C3.ai, Inc. (AI). AI is in the middle of its own short squeeze and has nearly doubled into $40's since Kerrisdale tried taking it down: The AI report is still featured alongside on the CVNA one on Kerrisdale's website , so we can assume this position
Read more

The Next NVDA-Backed Runner and New Asian IPO Squeeze Play

Image
We have seen stocks like Super Micro Computer, Inc. (SMCI) and SoundHound AI, Inc. (SOUN) have incredible squeeze runs thanks to their connection to NVIDIA Corporation (NVDA). We think the next one will be Spire Global, Inc. (SPIR), which popped a week ago after it announced a collaboration with NVDA to enhance AI-driven weather prediction. A few day later it dropped on the announcement of a financing at $14, with the potential to raise $61 million if warrants at $14.50 are exercised. We think there is a good chance that NVDA got in on this financing, as it tends to invest in the companies it does these deals with when spreading AI across different sectors. One such recent example was with Recursion Pharmaceuticals, Inc. (RXRX) for AI in drug development.  It looks like SPIR didn't really need this financing as it has enough cash and looks like it will be cash flow and net income positive in 2024. This financing was of a strategic nature, not something led by brokers to fund a com
Read more

CVNA Squeezing, ROOT and RXRX are Next

Image
Earlier today we stated that Root, Inc. (ROOT) and Recursion Pharmaceuticals, Inc. (RXRX) were next to squeeze after Carvana (CVNA). One month ago  we mentioned  the gamma squeeze potential on CVNA. Now that this is at hand and the stock has more than doubled, it's time to go long on two other heavily shorted stocks that stand to benefit from the CVNA squeeze as desperate shorts have to cover.  The strategy worked perfectly as ROOT increased 19% and RXRX increased 16% on the day while CVNA rose another 40%. This will be just the beginning as shorts are hemorrhaging on multiple related positions. If you look at the chart for the day, it becomes very clear how highly correlated these three stocks are right now. This is undeniably a sign that shorts, particularly algo HFT shorts are covering simultaneously held positions.  CVNA  made a $126 million investment  into ROOT and has embedded its insurance program into its systems. So any improvement in financial performance on CVNA implie
Read more